Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of intra-arterial autologous mesoangioblasts for biceps weakness in m.3243A>G mitochondrial disease
NL-OMON55910Phase 2Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous mesoangioblasts in Mitochondrial myopathies (MM) and Mitochondriopathy, sponsored by Maastricht University Medical Center+. Primary endpoints: Muscle strength and fatigue efficacy and Safety of ATMP and intra-arterial administration. Started Nov 2023; status: recruiting.
02
Drugs
autologous mesoangioblasts
03
Conditions
Mitochondrial myopathies (MM)Mitochondriopathy
Beyond the preview
Go deeper on NL-OMON55910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55910.